New Anticancer Drugs

- of U.S

- Japan Joint Meeting on Phase I and II Clinical Trials

- The New NCI Screen and Its Implications for Clinical Evaluation

- The National Cancer Institute's Natural Products Antineoplastic Development Program

- Methodology of Phase I Study in Japan

- Methodology of Phase II Clinical Trial in Cancer

- Phase II Study of Antineoplastic Agents in Japan

- Clinical Strategy for Evaluation of Anthracycline Analogues

- Preliminary Clinical Study of Aclacinomycin A

- Preclinical and Clinical Studies on Chlorozotocin, a New Nitrosourea with Decreased Bone Marrow Toxicity

- Continuation of Phase II Study of 1-(4-Amino-2-Methylpyrimidine-5-yl)-Methyl-3-(2-Chloroethyl)-3-Nitrosourea Hydrochloride (ACNU)

- Review of Experimental Studies on Nitrosourea Derivates in Japan

- The Clinical Evaluation of Analogues, IV. Nitrosoureas

- Review of a New Antimetabolic Agent, 1-Hexylcarbamoyl-5-Fluorouracil (HCFU)

- Review of a New Antimetabolic Agent, 1,1-Bis(Tetrahydro-2-Furanyl)-5-Fluoro-2,4-Pyrimidinedione (FD-1)

- Effect and Mode of Action of N4-Behenoyl-?-D-Arabinofuranosylcytosine

- Strategy for Evaluation of a New Antitumor Agent in the Treatment of Breast Cancer

- Current Status of Breast Cancer Chemotherapy in Japan

- Present Status of Lung Cancer Chemotherapy in Japan

- Clinical Strategies in the Chemotherapy of Gastrointestinal Cancer

- Clinical Evaluation Strategy in Specific Disease Types - Clinical Study of Gastrointestinal Cancer Chemotherapy in One Institute of Japan

- A Review of Therapeutic Strategies for Phase I-II Trials in Genitourinary Cancer

- Recent Results of Using a Sequential Combination of Bleomycin and Mitomycin C in the Treatment of Metastatic Cervical Cancer

- Pharmacologic and Clinical Studies of N4-Behenoyl-1-Beta-D-Arabinofuranosylcytosine